Skip to main content

Table 1 Clinical characteristics of MYCN amplified cases

From: High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma

Case

Sex

Age at Diagnosis

Diagnosis

Location at Diagnosis

LMD at Diagnosis

Spine involvement

Recurrences

Location of recurrence

Followup

Disease Status

Prior Oncological Hx

1

M

52

A-EPN (grade III)

T, B

Yes

ID, EM

0

NA

2

Alive

Basal Cell Ca

2

F

24

A-EPN (grade III)

C, T, L

Yes

ID, EM

0

NA

14

Alive

None

3

F

30

A-EPN (grade III)

T

No

ID, IM

3

T

17

Alive

None

4a

M

36

A-EPN (grade III)

T

No

unknown

4

C, LS

55

Alive

None

5

F

37

A-EPN (grade III)

T

No

ID, EM

3

T, B

62

Alive

None

6

F

35

A-EPN (grade III)

C, T

No

ID, EM

2

T

63

Alive

None

7

M

52

A-EPN (grade III)

C, T, L

Yes

ID, EM

1

C, T, L

80

Deceased

None

8

M

29

A-EPN (grade III)

C

Yes

ID, EM

12

C, B

85

Deceased

None

  1. a Case from CERN archive
  2. Abbreviations: LMD leptomeningeal disease, T thoracic, B brain, C cervical, L lumbar, LS lumbosacral, ID Intradural, EM extramedullary, IM Intramedullary